WO2024141952 - A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER
National phase entry:
Publication Number
WO/2024/141952
Publication Date
04.07.2024
International Application No.
PCT/IB2023/063289
International Filing Date
27.12.2023
Title **
[English]
A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER
[French]
INHIBITEUR DE FIBROBLASTE (CAF) ASSOCIÉ AU CANCER DESTINÉ À ÊTRE UTILISÉ AVEC UN CHAMP ÉLECTRIQUE ALTERNATIF DANS UNE MÉTHODE DE TRAITEMENT DE MALADIES TELLES QUE LE CANCER
Applicants **
NOVOCURE GMBH
Inventors
AVIGDOR, Lilach
KLEIN-GOLDBERG, Anat
VOLOSHIN-SELA, Tali
PAZ, Rom
Priority Data
63/477,565
29.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1332 | |
| EPO | Filing, Examination | 5087 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3310 |
Total:
10,893
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed are methods of treating a subject in need thereof comprising applying an alternating electric field, at a frequency for a period of time, to a target site of the subject in need thereof; and administering a cancer associated fibroblast (CAE) inhibitor to the subject in need thereof. Disclosed are methods of reducing or preventing CAE activation comprising applying alternating electric fields, at a frequency for a period of time, to a population of cells comprising one or more fibroblasts; and contacting a CAE activation inhibitor to the population of cells. Disclosed are methods of reducing CAE signaling comprising applying alternating electric fields, at a frequency for a period of time, to a population of cells comprising one or more fibroblasts; and contacting a cancer associated fibroblast (CAE) signaling inhibitor to the population of cells.[French]
La divulgation concerne des méthodes de traitement d'un sujet en ayant besoin, consistant à appliquer un champ électrique alternatif, à une certaine fréquence pendant une certaine période, au niveau d'un site cible du sujet en ayant besoin ; et à administrer un inhibiteur de fibroblastes associés aux cancers (CAE) au sujet en ayant besoin. La divulgation concerne des méthodes de réduction ou de prévention de l'activation de CAE consistant à appliquer des champs électriques alternatifs, à une certaine fréquence pendant une certaine période, à une population de cellules comprenant un ou plusieurs fibroblastes ; et à mettre en contact un inhibiteur d'activation de CAE avec la population de cellules. La divulgation concerne des méthodes de réduction de la signalisation CAE consistant à appliquer des champs électriques alternatifs, à une certaine fréquence pendant une certaine période, à une population de cellules comprenant un ou plusieurs fibroblastes ; et à mettre en contact un inhibiteur de signalisation des fibroblastes associés aux cancers (CAE) avec la population de cellules.